UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 659

Sortiert nach

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet neurology, 2014-06, Vol.13 (6), p.545-556

2014

Link zum Volltext

Verfügbarkeit prüfen

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

JAMA neurology, 2015-12, Vol.72 (12), p.1458

2015

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase

ChemMedChem, 2007-01, Vol.2 (1), p.58-61

2007

Link zum Volltext

Verfügbarkeit prüfen

Chemical proteomics and its application to drug discovery

Current opinion in biotechnology, 2003-02, Vol.14 (1), p.87-95

2003

Link zum Volltext

Verfügbarkeit prüfen

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS

Journal of neurology, 2016-02, Vol.263 (2), p.299-305

2016

Link zum Volltext

Verfügbarkeit prüfen

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Neurology, 2017-10, Vol.89 (15), p.1584

2017

Link zum Volltext

Verfügbarkeit prüfen

US Food and Drug Administration Perspectives on Clinical Mass Spectrometry

Clinical chemistry (Baltimore, Md.), 2016-01, Vol.62 (1), p.41-47

2016

Link zum Volltext

Verfügbarkeit prüfen

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

Journal of neurology, 2016-07, Vol.263 (7), p.1418-1426

2016

Link zum Volltext

Verfügbarkeit prüfen

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

BMJ open, 2020-10, Vol.10 (10), p.e038861-e038861

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Lancet neurology, 2008-10, Vol.7 (10), p.903-914

2008

Link zum Volltext

Verfügbarkeit prüfen

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

Expert review of neurotherapeutics, 2016-01, Vol.16 (1), p.31-44

2016

Link zum Volltext

Verfügbarkeit prüfen

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

Angewandte Chemie (International ed.), 2011-06, Vol.50 (26), p.5889-5891

2011

Link zum Volltext

Verfügbarkeit prüfen

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy

Therapeutic Advances in Chronic Disease, 2013-01, Vol.4 (1), p.45-51

Jeffery, Douglas R.

2013

Link zum Volltext

Verfügbarkeit prüfen

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

BMC neurology, 2013-07, Vol.13 (1), p.80-80, Article 80

2013

Link zum Volltext

Verfügbarkeit prüfen

Interleukin 17F level and interferon β response in patients with multiple sclerosis

JAMA neurology, 2013-08, Vol.70 (8), p.1017

2013

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Proteomic Verification of Membrane Proteins as Potential Therapeutic Targets Located in the 11q13 Amplicon in Cancers

Journal of proteome research, 2015-09, Vol.14 (9), p.3670-3679

2015

Link zum Volltext

Verfügbarkeit prüfen

“Product Ion Monitoring” Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap

Journal of proteome research, 2008-02, Vol.7 (2), p.640-647

2008

Link zum Volltext

Verfügbarkeit prüfen

Enzyme activity – it's all about image

Trends in cell biology, 2004, Vol.14 (1), p.29-35

2004

Link zum Volltext

Verfügbarkeit prüfen

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis

Journal of neuroimmunology, 2009-06, Vol.211 (1), p.124-130

2009

Link zum Volltext

Verfügbarkeit prüfen

The changing face of multiple sclerosis clinical trial populations

Current medical research and opinion, 2011-08, Vol.27 (8), p.1529-1537

2011

Link zum Volltext

Verfügbarkeit prüfen

Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies

Journal of neuroinflammation, 2012-06, Vol.9 (1), p.129-129, Article 572

2012

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapeutics in the treatment of multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2010-09, Vol.3 (5), p.277-291

2010

Link zum Volltext

Verfügbarkeit prüfen

Statin-associated exacerbation of myasthenia gravis

Neurology, 2004-12, Vol.63 (11), p.2188

2004

Link zum Volltext

Verfügbarkeit prüfen

Fingolimod for the treatment of relapsing multiple sclerosis

Expert review of neurotherapeutics, 2011-02, Vol.11 (2), p.165-183

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 659

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(593)
Mit Volltextzugriff
(578)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(408)
Life Sciences & Biomedicine
(343)
Humans
(238)
Male
(133)
Female
(127)
Biological And Medical Sciences
(122)
Medical Sciences
(93)
Animals
(89)
Adult
(88)
Middle Aged
(77)
Neurosciences & Neurology
(70)
Clinical Neurology
(58)
Neurology
(41)
Physical Sciences
(41)
Neurosciences
(40)
Aged
(39)
Biochemistry & Molecular Biology
(39)
Treatment Outcome
(36)
Fundamental And Applied Biological Sciences. Psychology
(32)
Multiple Sclerosis
(32)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Chemical proteomics and its application to drug discovery

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

US Food and Drug Administration Perspectives on Clinical Mass Spectrometry

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

Interleukin 17F level and interferon β response in patients with multiple sclerosis

Quantitative Proteomic Verification of Membrane Proteins as Potential Therapeutic Targets Located in the 11q13 Amplicon in Cancers

“Product Ion Monitoring” Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap

Enzyme activity – it's all about image

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis

The changing face of multiple sclerosis clinical trial populations

Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies

Chemotherapeutics in the treatment of multiple sclerosis

Statin-associated exacerbation of myasthenia gravis

Fingolimod for the treatment of relapsing multiple sclerosis

Suchergebnisse filtern